RADIONUCLIDE BRACHYTHERAPY SOURCE SYSTEMS FOR OCULAR RADIOTHERAPY

Radionuclide brachytherapy sources (RBS) for applying radiation to a target area, for example for treating macular edema (ME), diabetic retinopathy (DR), diabetic macular edema (DME), cystoid macular edema (CME), ME secondary to central retinal vein occlusion (CRVO), and ME secondary to branch retin...

Full description

Saved in:
Bibliographic Details
Main Authors JAGER, Rama D, MIMURA, George, HAMILTON, Russell J, DREW, Mary E, LOHRENZ, Ryan L, CHHABLANI, Jay, STEA, Baldassarre D
Format Patent
LanguageEnglish
French
Published 02.05.2024
Subjects
ADHESIVES
BANDAGES, DRESSINGS OR ABSORBENT PADS
CHEMISTRY
DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS
DYES
FILTERS IMPLANTABLE INTO BLOOD VESSELS
FIRST-AID KITS
FOMENTATION
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MISCELLANEOUS APPLICATIONS OF MATERIALS
MISCELLANEOUS COMPOSITIONS
NATURAL RESINS
ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES
PAINTS
POLISHES
POLISHING COMPOSITIONS OTHER THAN FRENCH POLISH
PROSTHESES
SKI WAXES
TREATMENT OR PROTECTION OF EYES OR EARS
Online AccessGet full text

Cover

More Information
Summary:Radionuclide brachytherapy sources (RBS) for applying radiation to a target area, for example for treating macular edema (ME), diabetic retinopathy (DR), diabetic macular edema (DME), cystoid macular edema (CME), ME secondary to central retinal vein occlusion (CRVO), and ME secondary to branch retinal vein occlusion (BRVO). The RBSs provided herein are useful for decreasing vascular permeability while minimizing adverse effects associated with radiotherapy, thereby providing advantages over existing brachytherapy sources. L'invention concerne des sources de curiethérapie à radionucléides (RBS) pour appliquer un rayonnement sur une zone cible, par exemple pour traiter un oedème maculaire (ME), une rétinopathie diabétique (DR), un oedème maculaire diabétique (DME), un oedème maculaire cystoïde (CME), un ME secondaire par rapport à une occlusion de veine rétinienne centrale (CRVO) et un ME secondaire par rapport à une occlusion de veine rétinienne ramifiée (BRVO). Les RBS selon l'invention sont utiles pour diminuer la perméabilité vasculaire tout en minimalisant les effets secondaires associés à la radiothérapie, ce qui procure des avantages par rapport à des sources existantes de curiethérapie.
Bibliography:Application Number: WO2023US35967